エボテックADRの適時開示

6-K 1 evo_6k.htm FORM 6-K evo_6k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MAY 2023

COMMISSION FILE NUMBER 001-34041

Evotec SE

(Translation of registrant’s name into English)

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

Explanatory Note

On May 09, 2023, Evotec SE issued an Ad-Hoc announcement stating that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. A copy of the Ad-Hoc announcement is attached as Exhibit 99.1 hereto. A copy of the accompanying press release is attached as Exhibit 99.2 hereto.

SIGNATURE

Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Evotec SE

	By:	/s/ Laetitia Rouxel
		Name: Laetitia Rouxel
		Title: Chief Financial Officer

Date: 9th May 2023

EXHIBIT INDEX

Exhibit		Description of Exhibit

99.1		Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
99.2		Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing

EX-99.1 2 evo_ex991.htm EX-99.1 evo_ex991.htm

EXHIBIT 99.1

Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz

Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.

The partnership includes an option for the non-exclusive in-licensing of Just – Evotec Biologics’ proprietary J.DESIGN technology by Sandoz to build a state-of-the-art, ‘S.POD’ facility fully owned by Sandoz in the latter part of this decade.

Just – Evotec Biologics will receive a double-digit-million upfront and future payments of US$ 640 m dependent on successful development progress as well as additional undisclosed payments dependent on progress into commercial manufacturing and exercise of the licensing option.

- End of the ad hoc release –

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, Email: werner.lanthaler@evotec.com

EX-99.2 3 evo_ex992.htm EX-99.2 evo_ex992.htm

EXHIBIT 99.2